Acute Bacterial Skin and Skin Structure Infection Clinical Trial
Official title:
An Open-Label Study to Evaluate the Safety of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) in Subjects on Concomitant Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
This was a Phase 4, multicenter, open-label safety study of a single 1200 milligrams (mg) IV infusion of oritavancin in adult participants on chronic warfarin with acute bacterial skin and skin structure infection (ABSSSI) suspected or proven to be caused by Gram-positive pathogens. An additional group of participants with ABSSSI, who were not on concomitant warfarin therapy, were also enrolled to obtain additional information following a single dose of oritavancin administration.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04298463 -
Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI
|
||
| Recruiting |
NCT05599295 -
Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin
|
Phase 2 | |
| Completed |
NCT03233438 -
Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
|
Phase 4 | |
| Completed |
NCT03873987 -
Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients
|
Phase 1 | |
| Not yet recruiting |
NCT04229511 -
Development of Risk Score Model and Decision Tree Algorithm for Predicting Infections With CRKp in Colonized Patients
|